Skip to content

Author

S. Lonardi

We have 5 of 750 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Sociodemographic and clinical factors associated with health-related quality of life among patients with colorectal cancer: a multicentre cross-sectional study in Italy

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide. The disease and its treatments significantly impact patients' quality of life (QoL), including physical, psychological, and social functioning. Patient-Reported Outcome Measures (PROMs) complement clinical assessments. T...

M. Di Nitto, G. Chiloiro, D. D'Angelo et al. · 0 citations
Open access Nov 2026

Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials

Background In resected liver-limited metastatic colorectal cancer (LL-mCRC), disease-free survival (DFS) and postsurgical overall survival (psOS) have been found to be weakly related in heterogeneous retrospective series, challenging the role of DFS as a surrogate biomarker of psOS. Additionally, it remains unclear whe...

M. Germani, A. Taravella, D. Rossini et al. · 0 citations
Open access Oct 2026

The impact of PROgnostic SIgnatures in stage II colon cancer patients enrolled in the phase III clinical trial TOSCA: the PROSIT study.

BACKGROUND Adjuvant chemotherapy (ACT) indication in stage II colorectal cancer (CRC) remains challenging, as clinical, pathological, and ctDNA inadequately predict benefit. Immune infiltration correlates with outcome, yet transcriptional signatures have not been systematically evaluated in prospective trial cohorts. W...

A. Puccini, L. Ferrando, G. Frige' et al. · 0 citations
Open access Oct 2026

Adjuvant chemotherapy with cisplatin and gemcitabine compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).

CisGem did not statistically improve DFS compared to capecitabine and should thus not be applied as standard of care in the adjuvant setting and should thus not be applied as standard of care in the adjuvant setting.

A. Stein, J. Bridgewater, H. Klümpen et al. · 1 citation
Aug 2026

Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.

High baseline circulating and tumor γδ T cells and early circulating CD8⁺PD-1⁺ T Cell expansion were associated with better outcome under AtezoBev, and an early induction of T cell-associated interferon-γ signaling at 3 weeks after the first injection of AtezoBev in patients that experienced response.

I. Galy-Fauroux, A. Asif-Laidin, M. Evain et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.